Capricor Therapeutics Inc sell nvestor
Start price
01.10.19
/
50%
€3.36
Target price
12.10.19
€0.000
Performance (%)
-32.14%
End price
12.10.19
€2.28
Summary
This prediction ended on 12.10.19 with a price of €2.28. nvestor correctly predicted massive losses of -32.14% for Capricor Therapeutics Inc. nvestor has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Capricor Therapeutics Inc | 19.305% | 19.305% | -21.706% | 15.875% |
iShares Core DAX® | 1.510% | 2.268% | 18.541% | 18.577% |
iShares Nasdaq 100 | -0.271% | -1.533% | 22.755% | 34.901% |
iShares Nikkei 225® | -0.108% | 0.411% | 10.352% | -0.876% |
iShares S&P 500 | 0.479% | 0.563% | 22.881% | 38.847% |
According to nvestor what are the pros and cons of Capricor Therapeutics Inc for the foreseeable future?
Pros
Cons
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
Little Investments for future growth
Risky balance sheet
Bad rating
ROE lower than 10% per year
Below average Management
Few uniques
Dependend from some customers or products
Sustainability is little important
Higher risks for its business
Below average Marketposition
Significant cyclical dependencies
Little known brand
Business model of the past or high risk
Probably not worthwhile Investment
Revenue decline/stagnation expected
negative Cash Flow expected
Increased challenges to pay loans and raise capital
Bad culture
Little innovation
high free float
Growths slower than the competition
Comments by nvestor for this prediction
In the thread Capricor Therapeutics Inc diskutieren
Sell mit Kursziel 0,0
Sell beendet
Stopped prediction by nvestor for Capricor Therapeutics Inc
Capricor Therapeutics Inc
Start price
Target price
Perf. (%)
€3.32
30.09.23
30.09.23
€1.00
30.09.24
30.09.24
-17.17%
14.10.23
14.10.23
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
Capricor Therapeutics Inc
Start price
Target price
Perf. (%)
€7.10
25.07.20
25.07.20
€3.00
08.08.20
08.08.20
-29.86%
08.08.20
08.08.20
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected